Figure 1.
Response evolution between interim evaluation and best-achieved results in patients treated frontline (panel (A)) and in those receiving ibrutinib as a second line or beyond (panel (B)). Y-axis represents patients %.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.